Overview of FLAURA and MARIPOSA-2 Clinical Trials

Opinion
Video

Dr. Kim reviews key clinical evidence from the FLAURA trial for osimertinib as a first-line therapy in EGFR+ metastatic NSCLC and discusses the MARIPOSA 2 trial supporting amivantamab with chemotherapy as the preferred second-line option.

Video content above is prompted by the following:

  • Provide an overview of the clinical evidence from the FLAURA trial supporting osimertinib as a first-line treatment for EGFR+ metastatic NSCLC.
  • Review the evidence from the MARIPOSA-2 trial supporting amivantamab plus chemotherapy as the best second-line option for this patient.
Recent Videos
Related Content
A single-arm phase 2 study assessed local consolidative therapy regimens in patients with oligometastatic stage IV non–small cell lung carcinoma.

Local Consolidative Therapy Combo May Extend Survival in Stage IV NSCLC

Roman Fabbricatore
January 22nd 2025
Article

A single-arm phase 2 study assessed local consolidative therapy regimens in patients with oligometastatic stage IV non–small cell lung carcinoma.

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Optimizing NSCLC Outcomes Via Technological Advances in Radiation Oncology

Terence T. Sio, MD, MS
June 3rd 2024
Podcast

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Results from a Chinese phase 1 trial reveal that anlotinib plus EGFR-TKIs demonstrated manageable toxicity in NSCLC pre-treated with EGFR-TKIs.

Anlotinib Prolongs EGFR-TKI Clinical Benefit in Advanced NSCLC

Roman Fabbricatore
January 21st 2025
Article

Results from a Chinese phase 1 trial reveal that anlotinib plus EGFR-TKIs demonstrated manageable toxicity in NSCLC pre-treated with EGFR-TKIs.

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Moving The Needle in Lung Cancer Management With Robotic-Assisted Surgery

Richard Lazzaro, MD
April 22nd 2024
Podcast

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Advancement of First-Line Treatments on EGFR-Mutated NSCLC

Advancement of First-Line Treatments on EGFR-Mutated NSCLC

ONCOLOGY Staff
January 17th 2025
Article

As part of a Satellite Sessions program focused on the Cleveland Clinic and surrounding institutions, CancerNetwork hosted a panel discussion on treatment options for patients with EGFR-mutated NSCLC.

NSCLC Experts Ponder Best First-Line Treatment Options

NSCLC Experts Ponder Best First-Line Treatment Options

ONCOLOGY Staff
January 17th 2025
Article

The discussion on NSCLC narrowed in on findings from recent clinical trials, particularly involving a combination regimen of amivantamab plus lazertinib vs osimertinib and chemotherapy.